SANTONI, MASSIMO
 Distribuzione geografica
Continente #
NA - Nord America 328
EU - Europa 179
AS - Asia 103
OC - Oceania 3
AF - Africa 1
SA - Sud America 1
Totale 615
Nazione #
US - Stati Uniti d'America 319
IE - Irlanda 135
CN - Cina 75
FI - Finlandia 23
SG - Singapore 20
CA - Canada 9
DE - Germania 7
IT - Italia 6
JP - Giappone 5
SE - Svezia 3
AU - Australia 2
GB - Regno Unito 2
AR - Argentina 1
BG - Bulgaria 1
HK - Hong Kong 1
IL - Israele 1
MU - Mauritius 1
MY - Malesia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
Totale 615
Città #
Dublin 135
Chandler 87
Beijing 52
Ashburn 34
Helsinki 23
Boardman 22
Lawrence 20
Medford 20
Princeton 20
Shanghai 19
Singapore 16
Wilmington 11
Toronto 8
Dearborn 5
Tokyo 5
Chicago 4
Norwalk 3
Canberra 2
London 2
Milan 2
Cambridge 1
Cedar Knolls 1
Changsha 1
Dallas 1
Fairfield 1
Guangzhou 1
Gunzenhausen 1
Hong Kong 1
Jerusalem 1
Los Angeles 1
Nanchang 1
Ottawa 1
Pavia 1
Pinehaven 1
Piscataway 1
Pognana Lario 1
Saint Petersburg 1
San Francisco 1
Santa Clara 1
Sofia 1
Torino 1
Totale 511
Nome #
Clinical impact of Pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis 41
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 40
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 39
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 35
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents 35
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 35
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 34
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? 34
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma 34
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises 33
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 32
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 32
Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma 31
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 30
Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis 30
Transplantation of kidneys with tumors 27
Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis 27
Toward a genome-based treatment landscape for renal cell carcinoma 24
Renal cancer in kidney transplanted patients 22
Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End 22
Totale 637
Categoria #
all - tutte 4.588
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.588


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202079 0 0 0 0 0 0 21 6 0 24 28 0
2020/20214 0 1 0 0 0 0 0 3 0 0 0 0
2021/202285 3 0 9 0 1 0 1 5 2 3 15 46
2022/2023296 34 32 5 8 14 25 0 15 152 3 6 2
2023/2024111 21 18 3 5 10 25 12 4 0 1 3 9
2024/202562 20 22 14 4 2 0 0 0 0 0 0 0
Totale 637